GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » 3-Year FCF Growth Rate

Oncopeptides AB (Oncopeptides AB) 3-Year FCF Growth Rate : 47.20% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB 3-Year FCF Growth Rate?

Oncopeptides AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 47.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Oncopeptides AB was 47.20% per year. The lowest was -105.60% per year. And the median was -44.10% per year.


Competitive Comparison of Oncopeptides AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Oncopeptides AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's 3-Year FCF Growth Rate falls into.



Oncopeptides AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Oncopeptides AB  (OTCPK:ONPPF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Oncopeptides AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB (Oncopeptides AB) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB (Oncopeptides AB) Headlines

From GuruFocus

Invitation to presentation of Q1 report

By PRNewswire PRNewswire 04-27-2022

Oncopeptides has announced the Nomination Committee

By PRNewswire PRNewswire 12-22-2022

Oncopeptides publishes Q1 report 2022

By PRNewswire PRNewswire 05-04-2022

Oncopeptides announces year-end cash 2021

By PRNewswire PRNewswire 01-05-2022

Number of shares and votes in Oncopeptides

By PRNewswire PRNewswire 07-29-2022

Oncopeptides publishes Q3 report 2022

By PRNewswire PRNewswire 11-09-2022